Blood tests to screen older adults in the community for Alzheimer's disease
Checks how well blood markers screen older community adults for Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Community-based Screening for Alzheimer's Disease
Key facts
- Where
- Shanghai, ChinaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 80 years old?
Source: NCT07570719, who can take part
Where in China
- Fengcheng Community Health Service CenterShanghai, ChinaTaking people
- Fengpu Community Health Service CenterShanghai, ChinaTaking people
- Qingcun Community Health Service CenterShanghai, ChinaTaking people
- Xidu Community Health Service CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kuang XiaoJun
- Trial code
- NCT07570719
- Record updated
- 6 November 2026
- Original description
The goal of this prospective, multicenter, observational cohort study is to evaluate the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults.Read full original descriptionShow less
Stratified Screening of Blood Biomarkers for Alzheimer's Disease: a Prospective, Real World, Community-based Study
The goal of this prospective, multicenter, observational cohort study is to evaluate the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults.
The main questions it aims to answer is:
What is the clinical screening value of blood biomarkers (phosphorylated tau 217 to amyloid β 42 ratio [pTau217/Aβ42] and glial fibrillary acidic protein [GFAP]) for AD among community-dwelling older adults? Eligible study participants will be randomly enrolled from community-dwelling older adults undergoing routine physical examinations and outpatient clinic attendees. All enrolled participants will undergo AD screening via blood biomarker testing. Participants with positive blood biomarker results (defined as abnormal pTau217/Aβ42 ratio and/or GFAP levels) will further complete a full battery of cognitive scale assessments, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Activities of Daily Living (ADL) scale, and 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, 15% of participants with negative blood biomarker results, selected via random sampling, will also complete the same cognitive scale assessments.
Inclusion: Aged 60-80 years; Capable of normal communication and able to complete the questionnaire.
Exclusion: Severe mental disorders; Severe renal insufficiency, heart failure, cerebrovascular disease, anemia, hyperthyroidism, hypothyroidism; Multiple cerebral infarctions, severe white matter hyperintensities, history of cerebral hemorrhage, current anticoagulant use, MRI abnormalities (cortical iron deposition, cerebral contusion); Severe visual, auditory, comprehension or mobility impairments; Current participation in other health intervention clinical studies; Unable to comply with study procedures with no legal guardian.